IBD Stock Overview
Northern Lights Fund Trust IV - Inspire Corporate Bond ETF is an exchange traded fund launched by Northern Lights Fund Trust IV.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Northern Lights Fund Trust IV - Inspire Corporate Bond ETF Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$23.07 |
52 Week High | US$24.62 |
52 Week Low | US$21.95 |
Beta | 0 |
1 Month Change | -1.54% |
3 Month Change | -1.96% |
1 Year Change | -0.90% |
3 Year Change | -11.58% |
5 Year Change | -8.20% |
Change since IPO | -8.09% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
IBD | US Capital Markets | US Market | |
---|---|---|---|
7D | -0.5% | -2.6% | -3.7% |
1Y | -0.9% | 22.7% | 20.5% |
Return vs Industry: IBD underperformed the US Capital Markets industry which returned 22.2% over the past year.
Return vs Market: IBD underperformed the US Market which returned 20.2% over the past year.
Price Volatility
IBD volatility | |
---|---|
IBD Average Weekly Movement | 1.2% |
Capital Markets Industry Average Movement | 3.4% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.4% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IBD has not had significant price volatility in the past 3 months.
Volatility Over Time: IBD's weekly volatility (1%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | n/a | n/a | www.inspireetf.com/ibd |
Northern Lights Fund Trust IV - Inspire Corporate Bond ETF is an exchange traded fund launched by Northern Lights Fund Trust IV. The fund is managed by Inspire Investing, LLC. It invests in fixed income markets of the United States.
Northern Lights Fund Trust IV - Inspire Corporate Bond ETF Fundamentals Summary
IBD fundamental statistics | |
---|---|
Market cap | US$258.05m |
Earnings (TTM) | US$0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs IBD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IBD income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$0 |
Earnings | US$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did IBD perform over the long term?
See historical performance and comparison